Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Additional Information (Details)

v3.23.1
Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
Program
PerformanceObligation
Mar. 31, 2020
USD ($)
May 31, 2019
USD ($)
Jul. 31, 2018
USD ($)
Program
Aug. 31, 2017
Program
Mar. 31, 2023
USD ($)
Installment
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
Apr. 30, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Accounts receivable, reserve for credit losses           $ 0   $ 0    
Vaxcyte, Inc.                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue           17,500,000   17,500,000    
Nonrefundable, non-creditable upfront payment receivable               $ 10,000,000.0    
Shares received | shares               167,780    
Common stock fair value               $ 7,500,000    
Additional nonrefundable and noncreditable payment           5,000,000.0        
Regulatory milestones cash in payment           $ 75,000,000.0        
Number of installments | Installment           2        
Additional milestone payment           $ 60,000,000.0        
BMS Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Number of programs advancing through preclinical development | Program         4          
Contingent payments     $ 275,000,000.0              
Deferred revenue           0   0    
2018 BMS Master Services Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue           1,200,000   3,100,000    
2018 Merck Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue           $ 0   0    
Milestone payment receivable upon initiation of IND enabling toxicology study                   $ 15,000,000.0
2018 Merck Agreement | Merck Sharp & Dohme Corp                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Number of target programs | Program       2            
Initial transaction price       $ 60,000,000.0            
Contingent payment received               10,000,000.0    
Milestone payment received               2,500,000    
Additional milestone payment received               7,500,000    
Revenue recognition aggregate contingent payments eligible to receive                 $ 500,000,000  
Milestone method revenue recognition description           If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration.        
First Cytokine-Derivative Program | Merck Sharp & Dohme Corp                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment received   $ 5,000,000.0                
Extended research term   1 year                
2020 Merck Master Services Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue           $ 0   0    
MDA Agreement | EMD Serono                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue           0   0    
Supply Agreement | Vaxcyte, Inc.                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Reimbursements expenses accruals           5,300,000   4,800,000    
Reimbursements expenses           1,900,000 $ 2,400,000      
Astellas License and Collaboration Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue           83,500,000   86,100,000    
Number of target programs | Program 3                  
Upfront payment received           90,000,000.0        
Transaction price $ 90,000,000.0                  
Estimated service period 4 years                  
Recognition of up front payment $ 89,100,000                  
Upfront payment revenue not recognized           32,600,000        
Nonrefundable, non-creditable upfront payment receivable               $ 90,000,000.0    
Number of performance obligations | PerformanceObligation 4                  
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate           $ 422,500,000        
Astellas License and Collaboration Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Recognition of up front payment $ 900,000